CClinicalTrials.gg
Status unknownNCT04881721Updated Mar 13, 2023

Mesh-free Suture Urethropexy for Treating Stress Urinary Incontinence, Efficacy and Durability Trial

An observational study in Stress Urinary Incontinence, sponsored by Endeavor Health. Status unknown at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-13.

Sponsored by Endeavor Health · Observational

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
15
Ages
18 Years and older
Sex
Female
01

Study summary

In this proposed study, the investigators aim to evaluate a modified suture urethropexy technique for the treatment of female stress urinary incontinence.

Participants will be followed with postoperative visits after 2 weeks, 2 months, and 12 months. Pelvic floor ultrasound imaging will be performed before surgery and after 2 months and 12 months, to evaluate urethral mobility.

Read the detailed description

This study is designed as a prospective observational study. The hypothesis is that suture urethropexy will improve stress urinary incontinence symptoms in participants with stress urinary incontinence and normal urethral closure pressure at 2 months and 12 months after surgery.

Specific Aims:

Aim 1: Investigate the efficacy of this mesh-free suture based surgical technique for improving SUI symptoms

Aim 2: Investigate the efficacy of this mesh-free suture based surgical technique on key urethral support defects observed with 3D ultrasound

02

Conditions studied

03

In context

Urinary Incontinence

1,363 studies on the registry are indexed under Urinary Incontinence; 228 are open to participants now.

This study's planned enrollment of 15 is below the median of 120 across 305 observational studies indexed under Urinary Incontinence.

Browse Urinary Incontinence studies →

Lead sponsor

Endeavor Health is the lead sponsor of 110 studies on the registry; 34 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 9 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants with female pelvic anatomy, 18 years or older, with stress dominant urinary incontinence interested and eligible for surgical treatment

Inclusion criteria

  • 18 years or older with stress dominant urinary incontinence
  • Stress urinary incontinence confirmed by testing (e.g. urodynamics)
  • Able to provide informed consent and attend post-operative visits

Exclusion criteria

Exclusion Criteria:

  • Detrusor overactivity (> 40cm H2O)
  • Maximum Urethral Closure Pressure (\< 40 cm H2O)
  • Post void residual > 150 mL
  • Prior surgery for stress urinary incontinence with retained material (e.g. bulking agent, sling)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
15 participants (estimated)
Patient registry
No

Interventions

  • ProcedureUrethropexy

    Suture based (Mesh-free) surgery to stabilize the urethra for the treatment of stress urinary incontinence

06

What researchers measure

Primary outcomes

  1. Stress urinary incontinence symptoms

    Severity of stress urinary incontinence symptoms by questionnaire

    Time frame: 2 weeks

  2. Stress urinary incontinence symptoms

    Severity of stress urinary incontinence symptoms by questionnaire

    Time frame: 3 months

  3. Stress urinary incontinence symptoms

    Severity of stress urinary incontinence symptoms by questionnaire

    Time frame: 12 months

  4. Voiding dysfunction

    Rate of urinary retention after surgery

    Time frame: Within 1 year of surgery

Secondary outcomes

  1. Distal Urethral Motion

    Distal urethral swing angle during Valsalva measured via pelvic ultrasound

    Time frame: 2 months

  2. Distal Urethral Motion

    Distal urethral swing angle during Valsalva measured via pelvic ultrasound

    Time frame: 12 months

  3. Proximal Urethral Motion

    Proximal urethral swing angle during Valsalva measured via pelvic ultrasound

    Time frame: 2 months

  4. Proximal Urethral Motion

    Proximal urethral swing angle during Valsalva measured via pelvic ultrasound

    Time frame: 12 months

  5. Post-operative complications

    Rate of post-operative complications

    Time frame: Within 1 year of surgery

07

Study locations

1 site
  • NorthShore University HealthSystem
    Skokie, Illinois 60076, United States
08

References and documents

Publications

  • Ford AA, Rogerson L, Cody JD, Aluko P, Ogah JA. Mid-urethral sling operations for stress urinary incontinence in women. Cochrane Database Syst Rev. 2017 Jul 31;7(7):CD006375. doi: 10.1002/14651858.CD006375.pub4. PubMed 28756647 ↗
  • Richter HE, Albo ME, Zyczynski HM, Kenton K, Norton PA, Sirls LT, Kraus SR, Chai TC, Lemack GE, Dandreo KJ, Varner RE, Menefee S, Ghetti C, Brubaker L, Nygaard I, Khandwala S, Rozanski TA, Johnson H, Schaffer J, Stoddard AM, Holley RL, Nager CW, Moalli P, Mueller E, Arisco AM, Corton M, Tennstedt S, Chang TD, Gormley EA, Litman HJ; Urinary Incontinence Treatment Network. Retropubic versus transobturator midurethral slings for stress incontinence. N Engl J Med. 2010 Jun 3;362(22):2066-76. doi: 10.1056/NEJMoa0912658. Epub 2010 May 17. PubMed 20479459 ↗
  • Kenton K, Stoddard AM, Zyczynski H, Albo M, Rickey L, Norton P, Wai C, Kraus SR, Sirls LT, Kusek JW, Litman HJ, Chang RP, Richter HE. 5-year longitudinal followup after retropubic and transobturator mid urethral slings. J Urol. 2015 Jan;193(1):203-10. doi: 10.1016/j.juro.2014.08.089. Epub 2014 Aug 23. PubMed 25158274 ↗
  • Nolfi AL, Brown BN, Liang R, Palcsey SL, Bonidie MJ, Abramowitch SD, Moalli PA. Host response to synthetic mesh in women with mesh complications. Am J Obstet Gynecol. 2016 Aug;215(2):206.e1-8. doi: 10.1016/j.ajog.2016.04.008. Epub 2016 Apr 16. PubMed 27094962 ↗
  • Frenkl TL, Rackley RR, Vasavada SP, Goldman HB. Management of iatrogenic foreign bodies of the bladder and urethra following pelvic floor surgery. Neurourol Urodyn. 2008;27(6):491-5. doi: 10.1002/nau.20558. PubMed 18537142 ↗
  • Brubaker L, Norton PA, Albo ME, Chai TC, Dandreo KJ, Lloyd KL, Lowder JL, Sirls LT, Lemack GE, Arisco AM, Xu Y, Kusek JW; Urinary Incontinence Treatment Network. Adverse events over two years after retropubic or transobturator midurethral sling surgery: findings from the Trial of Midurethral Slings (TOMUS) study. Am J Obstet Gynecol. 2011 Nov;205(5):498.e1-6. doi: 10.1016/j.ajog.2011.07.011. Epub 2011 Jul 20. PubMed 21925636 ↗
  • Baracat F, Mitre AI, Kanashiro H, Montellato NI. Endoscopic treatment of vesical and urethral perforations after tension-free vaginal tape (TVT) procedure for female stress urinary incontinence. Clinics (Sao Paulo). 2005 Oct;60(5):397-400. doi: 10.1590/s1807-59322005000500008. Epub 2005 Oct 24. PubMed 16254676 ↗
  • Giri SK, Drumm J, Flood HD. Endoscopic holmium laser excision of intravesical tension-free vaginal tape and polypropylene suture after anti-incontinence procedures. J Urol. 2005 Oct;174(4 Pt 1):1306-7. doi: 10.1097/01.ju.0000173926.04596.55. PubMed 16145408 ↗
  • Koduri S, Goldberg RP, Sand PK. Transvaginal therapy of genuine stress incontinence. Urology. 2000 Dec 4;56(6 Suppl 1):23-7. doi: 10.1016/s0090-4295(00)00509-4. PubMed 11114559 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04881721
Lead sponsor
Endeavor Health
Responsible party
Ghazaleh Rostami Nia (Director of Research Division of Urogynecology, NorthShore University HealthSystem, Endeavor Health) — Principal investigator
First posted
May 11, 2021
Start date
Aug 25, 2021
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Mar 13, 2023

Study contacts

Ghazaleh Rostami Nia, MD
principal investigator · Endeavor Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion